ALL
53 programs · 51 companies
Programs
53
Companies
51
Trials
49
MOAs
36
FXIaiIL-23iWEE1iTYK2iBiTECD3xCD20ALKiPRMT5iKIF18AiEGFRi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| BMY-9931 | Phase 1 | GPRC5D | ||
| Motarapivir | Preclinical | AuroraA | ||
| Doxafotisoran | Phase 1 | Cl18.2 | ||
| Sotosacituzumab | Phase 1 | MET | ||
| BII-8315 | NDA/BLA | CDK2 | ||
| ITC-1028 | Phase 2 | BCMA | ||
| Doxasotorasib | Phase 2/3 | CFTR | ||
| Teravorutinib | Phase 2 | JAK2 | ||
| RVM-274 | Phase 3 | MET | ||
| Terainavolisib | Preclinical | FXIa | ||
| Zenonaritide | Phase 1/2 | BCL-2 | ||
| Ivozasiran | Phase 2 | PLK4 | ||
| Zoricapivasertib | Phase 2 | HER2 | ||
| Nidaosocimab | Preclinical | Aβ | ||
| NCI-IIT-143 | Phase 1/2 | HER2 | ||
| NCI-IIT-512 | Approved | BCL-2 | ||
| MSK-IIT-373 | NDA/BLA | ALK | ||
| IMM-7074 | Phase 1/2 | WRN | ||
| Suraosocimab | Phase 1 | PSMA | ||
| ABL-1749 | Phase 1 | TROP-2 | ||
| Zenotuximab | Phase 1/2 | PI3Kα | ||
| TNY-3110 | Preclinical | KRASG12D | ||
| CLL-5354 | Preclinical | FcRn | ||
| APL-1567 | Approved | GIP-R | ||
| Cevicilimab | Phase 3 | B7-H3 | ||
| GLS-7714 | Approved | KRASG12C | ||
| Elracapivasertib | NDA/BLA | PARP | ||
| Polafotisoran | Phase 2/3 | PLK4 | ||
| DAS-6981 | Phase 2/3 | DLL3 | ||
| ASK-6688 | NDA/BLA | SGLT2 | ||
| Tezecapivasertib | Phase 1/2 | KRASG12D | ||
| REM-8705 | Preclinical | GLP-1R | ||
| Mirinaritide | Phase 2/3 | PD-L1 | ||
| Mavutuximab | Phase 1 | TIGIT | ||
| CAP-150 | NDA/BLA | PI3Kα | ||
| Tirazanubrutinib | NDA/BLA | MET | ||
| Rimacilimab | Phase 3 | USP1 | ||
| Talarasimod | Phase 3 | PI3Kα | ||
| 459-1094 | Phase 3 | BTK | ||
| SRR-6281 | Phase 1/2 | RET | ||
| MRE-7592 | Phase 1/2 | JAK1 | ||
| GNF-1172 | NDA/BLA | PRMT5 | ||
| 654-2851 | Preclinical | CD123 | ||
| Lisotuximab | Phase 2/3 | FcRn | ||
| CAD-5301 | Phase 1/2 | BCMA | ||
| SUV-9449 | Phase 3 | FcRn | ||
| Olpasacituzumab | Approved | SOS1 | ||
| Fixalucimab | Preclinical | TYK2 | ||
| CAM-IIT-432 | Preclinical | CDK4/6 | ||
| Fixatuximab | Approved | CDK2 | ||
| Miricilimab | Phase 2/3 | IL-17A | ||
| Adagratuximab | Phase 2 | APOC3 | ||
| BLC-3714 | Approved | CD38 |
Trials (49)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07139539 | Sotosacituzumab | Phase 1 | Recruiting |
| NCT06020175 | Sotosacituzumab | Phase 1 | Recruiting |
| NCT04453613 | Doxasotorasib | Phase 2/3 | Recruiting |
| NCT05175092 | Teravorutinib | Phase 2 | Terminated |
| NCT03799718 | Terainavolisib | Preclinical | Active |
| NCT07287544 | Terainavolisib | Preclinical | Terminated |
| NCT07504287 | Zenonaritide | Phase 1/2 | Completed |
| NCT03520455 | Zenonaritide | Phase 1/2 | Active |
| NCT07139390 | Ivozasiran | Phase 2 | Completed |
| NCT07996521 | Nidaosocimab | Preclinical | Completed |
| NCT05946323 | NCI-IIT-143 | Phase 1/2 | Active |
| NCT07412857 | NCI-IIT-512 | Approved | Active |
| NCT08694307 | MSK-IIT-373 | NDA/BLA | Not yet recr... |
| NCT03470565 | IMM-7074 | Phase 1/2 | Completed |
| NCT07378679 | ABL-1749 | Phase 1 | Recruiting |
| NCT04749678 | ABL-1749 | Phase 1 | Completed |
| NCT08714659 | Zenotuximab | Phase 1/2 | Completed |
| NCT07970999 | Zenotuximab | Phase 1/2 | Not yet recr... |
| NCT08030463 | APL-1567 | Approved | Recruiting |
| NCT03540193 | APL-1567 | Approved | Terminated |